



Penn Medicine

Continuing Medical and
Interprofessional Education

*The Penn Renal Electrolyte and Hypertension Division at
The Hospital of the University of Pennsylvania
Presents*

IN-PERSON AND VIRTUAL

NEW HORIZONS IN NEPHROLOGY: GLOMERULAR DISEASE 2026: THERAPEUTIC ADVANCES AND TARGETED APPROACHES

CME-ACCREDITED CONFERENCE

FRIDAY, SEPTEMBER 18, 2026

REGISTRATION • 7:30 - 7:50 AM

PROGRAM • 7:50 AM - 4:00 PM

In-Person Meeting Location

Smilow Center for Translational Research
Rubenstein Auditorium
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104


Course Co-Directors:

Gaia Coppock, MD

Abdallah Geara, MD

**Neph
sure** for Rare
Kidney
Disease

<https://upenn.cloud-cme.com/NewHorizons2026>



PROGRAM OVERVIEW & TARGET AUDIENCE

Glomerular disease is associated with morbidity and mortality in patients of all ages and is a common cause of end stage kidney disease. These include those that commonly present with nephrotic syndrome (minimal change disease, FSGS and membranous nephropathy), the nephritic syndrome (vasculitis, lupus nephritis and IgA nephropathy), among others. Treatment has evolved significantly over the last few years with approval of several targeted therapies limiting the use of other immunosuppressive regimens such as high dose corticosteroids, alkylating agents and calcineurin inhibitors. Thus, glomerular diseases present a difficult and unique challenge to both patients and nephrologists and are associated with high treatment costs and historically, have had poor renal outcomes. There have been significant recent advances in the field in both the diagnosis and treatment of glomerular diseases. Therefore, it is important for physicians to stay current with these new approaches to managing glomerular diseases.

This program has been designed for nephrologists and will address the latest updates and significant challenges of glomerular disease. A combination of case presentations and lectures will be used to provide an academically sound and clinically relevant review.


LEARNING OBJECTIVES

Upon conclusion of this educational activity, the participant will be better able to:

- Evaluate surrogate endpoints in glomerular diseases and apply them to assess treatment efficacy and trial design in clinical practice
- Identify and differentiate novel-non-immunological and targeted therapeutic approaches (including B-cell and complement pathway modulators) for managing glomerular diseases, and incorporate them into patient treatment strategies
- Describe the pathophysiology of podocytopathies (including minimal change disease and FSGS) IgA nephropathy, ANCA vasculitis, complement-mediated diseases (C3G, IC-MPGN, a HUS), lupus nephritis, and membranous nephropathy
- Integrate recent genetic insights to guide diagnosis and personalized management of glomerular diseases
- Analyze clinical cases of glomerular disease presentations, incorporating renal pathology findings, genetic testing results, and emerging biomarkers to formulate accurate differential diagnoses and evidence-based treatment plans
- Compare and contrast current and investigational therapies for glomerular diseases and discuss how to select appropriate patients for novel agents or clinical trials based on the latest mechanistic and outcome data.

HOSTING DEPARTMENT

New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches is hosted by the Renal Electrolyte and Hypertension Division of the Perelman School of Medicine at the University of Pennsylvania.



ACCREDITATION



In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACME), the Accreditation Council for Pharmacy Education (APE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

DESIGNATION OF CREDIT

Physicians: Penn Medicine designates this live activity for a maximum of 7.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PA's may receive a maximum of 7.75 Category 1 credits for completing this activity.

Certificates and Transcripts: After the conference has concluded, all participants will be marked as having attended and then will receive a follow-up email with instructions and a link with instructions on how to complete their post-test and evaluation then claim their credit. Once participants submit the request for credit, the earned credits will be available for viewing on your transcript or available for printing at <https://upenn.cloud-cme.com/NewHorizons2026>. Please note that the individual certificate will not be mailed.

LIVE AND VIRTUAL PRESENTATIONS

New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches will be held Friday, September 18, 2026, by in-person and live-stream virtual attendance. The in-person and virtual presentations will follow the scheduled agenda in real time (EDT).

IN-PERSON – MEETING LOCATION

New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches will be held at the University of Pennsylvania, in the Smilow Center for Translational Research, Rubenstein Auditorium, located in the Perelman Center for Advanced Medicine, 1st floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104.

LIVE-STREAM (VIRTUAL)

Attendees registered to attend virtually will receive an email 48 hours before the conference that includes the link to join the conference. All virtual attendees **are required to sign in with their first name, last name, and email address, in order to be marked as attended and receive credit.**



REGISTRATION FEES (IN-PERSON ATTENDANCE)

Please register online at

<https://upenn.cloud-cme.com/NewHorizons2026>

The fee to attend in-person is \$150 for all attendees. All pre-registered, in-person attendees will receive access to the conference, continental breakfast, lunch, and breaks. Registration also includes access to view the recorded speaker presentations online for one year. Walk-ins are discouraged. **Please register no later than September 16, 2026**, so an accurate count may be made for food and beverages.

REGISTRATION FOR LIVE-STREAM (VIRTUAL ATTENDANCE)

Please register online at <https://upenn.cloud-cme.com/NewHorizons2026>. The fee to attend virtually is \$100 and the **deadline to register virtually is also September 16, 2026**.

All registrants will receive conference materials via email 48 hours in advance of the meeting.

CANCELLATION AND REFUND POLICY

In order to process refunds for course withdrawals, cancellations must be received via email by September 11, 2026, and are subject to a service charge equivalent to 10% of the registration fee. No refunds will be issued thereafter. Please email nancy.wells@penmedicine.upenn.edu or evelyn.heldon@penmedicine.upenn.edu regarding cancellations.

The University of Pennsylvania reserves the right to cancel or postpone this course due to unforeseen circumstances. In the event of a cancellation or postponement, the University will refund registration fees but is not responsible for fees assessed for travel or hotels.

DIRECTIONS

The Smilow Center for Translational Research, Rubenstein Auditorium, is located in the Perelman Center for Advanced Medicine, 1st floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104.

Parking

Parking is available at the 3600 Civic Center Boulevard Garage at \$20 per day. A free shuttle service from the Parking garage to Perelman is also available.



FACULTY

With the exception of the guest faculty, the Course Directors & Faculty hold academic and/or clinical appointments from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine, Philadelphia, PA

COURSE CO-DIRECTORS

Gaia Coppock, MD

Assistant Professor of Clinical Medicine
Renal-Electrolyte & Hypertension Division

Abdallah Geara, MD

Associate Professor of Clinical Medicine
Renal-Electrolyte & Hypertension Division

GUEST FACULTY

Lara El-Khoury, MD

Assistant Professor of Medicine
Zucker School of Medicine at
Hofstra/Northwell
Division of Rheumatology
Great Neck, NY

Simone Sanna-Cherchi, MD

Associate Professor of Medicine
Columbia University
College of Physicians and Surgeons
Division of Nephrology
New York, NY

UNIVERSITY OF PENNSYLVANIA FACULTY

Kirk Campbell, MD

C. Mahlon Kline Professor of Medicine
Chief, Renal-Electrolyte &
Hypertension Division

Gaia Coppock, MD*

Assistant Professor of Clinical Medicine
Renal-Electrolyte & Hypertension Division

Clara Fischmann, MD

Associate Professor of Clinical Medicine
Renal, Electrolyte and Hypertension Division

Abdallah Geara, MD *

Associate Professor of Clinical Medicine
Renal, Electrolyte and Hypertension Division

Lawrence B. Holzman, MD

Professor of Medicine
Renal-Electrolyte & Hypertension Division

Ralph G. Nader, MD

Assistant Professor of Clinical Medicine
Renal-Electrolyte & Hypertension Division


Matthew B. Palmer, MD, PhD

Associate Professor of Pathology &
Laboratory Medicine

*Planning Committee Members

DISCLOSURES

Penn Medicine, Office of Continuing Medical and Interprofessional Education, adheres to the *ACCME Standards for Integrity and Independence in Accredited Continuing Education*. Faculty disclosure information will be made available in the conference materials and syllabi. Faculty members are also expected to disclose to participants any discussions of off-label and/or investigational uses of pharmaceutical products and devices within their presentations.




IN-PERSON AND VIRTUAL

NEW HORIZONS IN NEPHROLOGY: GLOMERULAR DISEASE 2026: THERAPEUTIC ADVANCES AND TARGETED APPROACHES

AGENDA | FRIDAY, SEPTEMBER 18, 2026

- 7:30 AM – 7:50 AM In-Person Registration/Continental Breakfast
Sign into the Virtual Platform (Virtual Attendees Only)
- 7:50 AM – 8:00 AM **Introduction**
Kirk Campbell, MD
- 8:00 AM – 8:25 AM **Surrogate End-Points in Glomerular Diseases**
Gaia Coppock, MD
- 8:25 AM – 8:50 AM **Novel Non-Immunological Approaches in Glomerular Disease**
Clara Fischmann, MD
- 8:50 AM – 9:15 AM **B-Cell Physiology and Potential Targets**
Ralph Nader, MD
- 9:15 AM – 9:40 AM **Complement Pathway Physiology and Potential Targets**
Ralph Nader, MD
- 9:40 AM – 9:50 AM **Ask the Panel**
*Gaia Coppock, MD, Clara Fischmann, MD
Abdallah S. Geara, MD and Ralph Nader, MD*
- 9:50 AM – 10:00 AM Break
- 10:00 AM – 10:15 AM **Case Presentation**
Abdallah S. Geara, MD and Mathew Palmer, MD, PhD
- 10:15 AM – 10:50 AM **Podocytopathy: Minimal Change Disease and FSGS**
Lawrence Holzman, MD
- 10:50 AM – 11:40 PM **Genetics in Glomerular Disease**
Simone Sanna-Cherchi, MD
- 11:40 AM – 11:50 AM **Ask the Panel**
*Abdallah S. Geara, MD, Lawrence Holzman, MD
Mathew Palmer, MD, PhD and Simone Sanna-Cherchi, MD*
- 11:50 AM – 12:30 PM Lunch Break



AGENDA *continued*

- 12:30 PM – 1:10 PM **IgA Nephropathy**
Kirk Campbell, MD
- 1:10 PM – 1:45 PM **ANCA Vasculitis**
Lara El-Khoury, MD
- 1:45 PM – 2:20 PM **Complement-Mediated Glomerular Disease: C3G, IC-MPGN and a HU**
Ralph Nader, MD
- 2:20 PM – 2:30 PM **Ask the Panel**
Kirk Campbell, MD, Lara El-Khoury, MD and Ralph Nader, MD
- 2:30 PM – 2:40 AM Break
- 2:40 PM – 3:15 PM **Lupus Nephritis**
Gaia Coppock, MD
- 3:15 PM – 3:45 PM **Membranous Nephropathy**
Abdallah S. Geara, MD
- 3:45 PM – 3:55 PM **Ask the Panel**
Gaia Coppock, MD and Abdallah S. Geara, MD
- 3:55 PM – 4:00 PM **Q&A and Final Remarks**
- 4:00 PM Adjourn

SERVICES FOR THE DISABLED If special arrangements are required for an individual with a disability to participate this meeting, please email nancy.wells@pennmedicine.upenn.edu no later than September 12, 2026.

NONDISCRIMINATION STATEMENT The University of Pennsylvania values diversity and seeks talented students, faculty, and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East Suite 228, Philadelphia, PA 19104-6106 or 215-898-6993 (Voice) or 215-898-7803 (TDD). www.upenn.edu/affirm-action.

IN-PERSON AND VIRTUAL

**NEW HORIZONS IN NEPHROLOGY:
GLOMERULAR DISEASE 2026:
THERAPEUTIC ADVANCES AND TARGETED APPROACHES**

FRIDAY, SEPTEMBER 18, 2026

REGISTRATION • 7:30 - 7:50 AM

PROGRAM • 7:505 AM - 4:00 PM

To register for the conference, please register online at
<https://upenn.cloud-cme.com/NewHorizons2026>

- A credit card will be required for registration.
We cannot accept faxed or mailed registration forms at this time.
- Registrations must be received by September 16, 2026.

For questions, please contact by email:

nancy.wells@penntmedicine.upenn.edu or evelyn.heldon@penntmedicine.upenn.edu

Please print or type

Name (First) _____ (Last) _____

Academic Degree _____

Medical Specialty _____

Affiliation (Hospital, Office, or Company) _____

Address (Affiliation or Home) _____

City _____ State _____ Zip _____

Phone _____ Fax _____

E-mail _____

REGISTRATION FEES

(pre-payment is required to be officially registered, early registration is recommended)

In-Person Attendance – \$150

Virtual Attendance – \$100

You must register to receive online access

Visit our meeting website at:

<https://upenn.cloud-cme.com/NewHorizons2026>